Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT

Author： Strojek Krzysztof   Bebakar Wan M.W.   Khutsoane Duma T.   Pesic Milica   Šmahelová Alena   Thomsen Henrik F.   Kalra Sanjay  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.12, 2009-12, pp. : 2887-2894

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes

By Yang Wenying   Xu Xiangjin   Liu Xiaomin   Yang Gangyi   Seino Yutaka   Andersen Henning   Jinnouchi Hideaki  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1599-1608

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 994-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 994-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite

Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24‐week, randomized, open‐label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape)

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 12, 2015-12 ,pp. : 1133-1141

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 1520-7552, Iss. 7, 2015-10 ,pp. : 725-733

John Wiley & Sons Inc

Access to resources Recommend Favorite